Biology of Mycobacterial Lipids covers various topics pertaining to the advancements and current research in the field of mycobacterial lipids, and on the significant progress in lipidomics, in recent times. The chapters present comprehensive, yet systematic cutting-edge research, comprising mycobacterial lipid terminologies, classifications, biosynthetic pathways, tools and techniques, and functional burgeoning. This unique reference book has contributions from pioneer researchers, experts, and eminent veterans from around the globe. It covers ground-breaking work that will bridge the gap between understanding biochemical patterns related to virulence, pathogenesis, and resistance and elucidating new targets for drug design, identifying biomarkers for predicting risk, early diagnosis, and therapeutic outcome.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.

This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.